You are here: Industry Insights > Roche

News List

Roche pulls EU application for Tecentriq in kidney cancer biopharmadive
November 22, 2018
Roche has withdrawn an application to the European Medicines Agency that sought an expanded approval for its immunotherapy Tecentriq in advanced kidney cancer, concluding in a letter to the regulator data were insufficient to support a label extension.
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma pharmafile
November 20, 2018
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin (bevacizumab) as a first-line treatment for renal cell carcinoma (RCC) due to insufficient
The top 10 cancer drug makers of 2024 fiercepharma
November 15, 2018
At first glance, the list of cancer drug makers predicted to head the field by 2024 may not look so different from the list of top-selling cancer drug makers in 2017.
Roche imports personalized health care to expo biospectrumasia
November 07, 2018
With the biggest booth in the Medical Equipment & Health Care Products Hall, Roche demonstrates a long-term commitment to Chinese patients and the Healthy China 2030 Initiative
FDA ups the ante on Roche blood thinner strips recall fiercebiotech
November 05, 2018
The FDA has slapped a Class I recall, its most serious and highest recall alert, for strips sold by Roche Diagnostics that are used to check warfarin...
Sales of Roche’s Rituxan Have Started to Decline as Biosimilars Thereof are Marketed 1℃
November 02, 2018
Celltrion and Teva Pharmaceutical released big news on October 11, 2018 that the Rituxan® (rituximab) biosimilar. After the marketing, CT-P10 will become the first Rituxan® (rituximab) biosimilar approved for marketing in the U.S.
Roche's eye drug beats Lucentis at Phase 2 in wet age-related macular degeneration pharmafile
October 31, 2018
Roche has revealed positive new Phase 2 data for faricimab (RG7716) in the treatment of neovascular (“wet”) age-related macular degeneration (nAMD), the most common cause of blindness in patients over 60 worldwide.
Roche's Alecensa topples Pfizer's Xalkori in Asian patients with ALK+ advanced lung cancer pharmafile
October 25, 2018
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small cell lung cancer...
Two trial wins for Roche’s immunotherapy Tecentriq pharmatimes
October 25, 2018
Roche’s immunotherapy Tecentriq (atezolizumab) has been shown to improve survival in lung cancer patients by almost five months in a new trial.
Roche takes on Loxo, Bayer in gene-defined cancer class expressbpd
October 23, 2018
The Roche compound is designed to tackle several oncogenic mutations

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page